International Journal of Medical and Pharmaceutical Research
2026, Volume-7, Issue 1 : 154-156
Case Report
Hemolytic Anemia Mimicker Came Out to be Gaucher Disease
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
Received
Dec. 9, 2025
Accepted
Dec. 26, 2025
Published
Jan. 11, 2026
Abstract

Gaucher Disease is a metabolic disorder, inheritance being autosomal recessive. It is the most common amongst Lysosomal storage diseases. It is caused by deficiency of acid Glucocerebrosidase(GBA) enzyme. Consequently accumulation of cerebroside occurs in phagocyte cells in reticuloendothelial system and in some variants of the disease in CNS. There are three subtypes, most common(99%) being type 1(non-neuronopathic form) presenting as hepatosplenomegaly, pancytopenia, failure to thrive and skeletal complications. Type 2,3 manifesting with neurologic symptoms. Diagnosis is by bone marrow aspiration or biopsy, enzymatic assay of beta-glucosidase and confirmation by genetic testing.

We describe a 3year3 month old male child who presented with gradual abdominal distension over a period of 18 months. Examination revealing hepatosplenomegaly with pallor and jaundice, failure to thrive. Haemolytic anemia was first thought of till HPLC came to be normal. Differentials were narrowed down to infiltrative disorders likely storage disorders like Gaucher disease, Niemann Pick disease. Possibility of leukemia, HLH was remote due to absence of fever, lymphadenopathy. Enzymatic assay depicted a normal sphingomyelinase level and lower normal beta glucocerebrosidase level, thus ruling in Gaucher disease. Bone marrow aspiration study showed Gaucher cells. Child presently receiving conservative management with initiation of process to receive enzyme replacement therapy(ERT).

Thus Gaucher disease should be considered a differential , not uncommon in patients with unexplained organomegaly, jaundice with anemia or pancytopenia

Keywords
INTRODUCTION

Gaucher disease is a multisystemic lipidosis, resulting from deficient activity of lysosomal hydrolase acid beta glucosidase, encoded by gene GBA. The enzymatic defect causes accumulation of undegraded glycolipid substrates in reticuloendothelial system with progressive infiltration of bone marrow, hepatosplenomegaly and skeletal complications.

 

There are three clinical subtypes on basis of absence or presence of neurologic manifestations- type 1, most common form(adult/ non neuronopathic), type 2 is infantile or acute neuronopathic form and type 3 is juvenile or subacute neuronopathic form. All being autosomal recessive in inheritance.

 

Type 1 GD presents with bruising from thrombocytopenia, chronic fatigue secondary to anemia, hepatomegaly with or without elevated LFT, splenomegaly and bone pain. Amongst skeletal manifestations, pathological fracture is common. Others being compression fracture of vertebral bodies, Erlenmeyer flask appearance of femur. Pulmonary infiltration may result in pulmonary failure. It is a premalignant state predisposing to lymphoproliferative diseases. Gaucher cell being pathologic hallmark have a characteristic wrinkled paper appearance due to intracytoplasmic substrate inclusions.

 

Type 2 GD characterised by rapid neurodegenerative disease and type 3 being classified as type 3a and 3b based on extent of neurologic disease-dementia and progressive myotonia(type 3a), isolated supranuclear gaze palsy(type 3b).

 

Diagnosis of type 1 GD can be done by bone marrow aspiration or biopsy showing gaucher cells, whereas definitive diagnosis of all types of GD requires assay of enzyme-acid beta glucosidase. Confirmation of diagnosis can be done by genetic testing.

 

Treatment of GD – Type 1 includes enzyme replacement therapy with recombinant acid beta glucosidase(Imiglucerase) which attenuates both skeletal as well as extraskeletal symptoms(organomegaly, hematologic indices)ERT is ineffective in Type 2 disease.

 

Other treatment options include substrate reduction therapy, chaperones, Piracetam, hip replacement(for avascular necrosis).

 

CASE STUDY

We present a case of 3 year 3 month old male child, fourth order in birth(birth weight -2.7kg), born out of consanguineous marriage, who came to visit for progressive painless abdominal distension for 18 months. Physical examination revealed- a coarse facies with pallor and icterus. Anthropometry recorded as weight 10.7 kg(-2 to-3 SD), height 67cm(<-3SD), weight for height(+2 to +3 SD). On abdominal examination, non tender hepatomegaly with liver span 13cm with firm consistency, smooth surface, sharp border. Spleen was enlarged and measured to be 14cm along splenic axis with palpable splenic notch. On laboratory examination, Hemoglobin was 7.3mg/dl, other blood cell indices remaining normal. HPLC was normal, blood glucose level normal, elevated PT, aPTT,INR levels, transaminitis with increased direct fraction of bilirubin. Skeletal survey was normal. Sphingomyelinase activity was normal while glucocerebrosidase level was at low-normal value. Bone marrow aspiration study showed Gaucher cells with normal hematopoetic activity. Genetic study could not be performed because of financial constraints. The child was supplemented with appropriate vitamins, iron folic acid and has been enrolled to avail enzyme replacement therapy.

 

 
   


 

 

DISCUSSION

In this case, normal HPLC; absence of fever, lymphadenopathy; absence of seizures and neuroregression; normal blood glucose level; normal skeletal survey ruled out possibilities of haemolytic anemia; hematologic malignancy; other storage disorders like Nieman Pick Disease, Glycogen storage diseases; Osteopetrosis.

 

Thus connecting consanguinity, coarse facies, age of presentation, chronic history, anemia, jaundice, hepatosplenomegaly in a 3 year 3 month old failure to thrive child with lower normal glucocerebrosidase level and Bone marrow aspiration study showing Gaucher cells points to diagnosis of Gaucher Disease Type1.

In case of anemia, jaundice, organomegaly the differentials to be thought of are-

 

1. Infections

Intrauterine infection in infants, Tropical

splenomegaly, Disseminated Tuberculosis

2.          Hemolysis

hematopoesis

and

extramedullary

 

3. Infiltrative

Non-neoplastic-storage osteopetrosis,HLH

 

Neoplastic-         Leukemia, Myelomonocytic Leukemia

 

 

 

LCH,

diseases,

 

 

Juvenile

4. Liver Disease

 

5. Immune Dysfunction

SLE, CVID,Sjia

           

 

Any under 5 child who presents with pallor, hepatosplenomegaly without fever after ruling out congenital haemolytic anemia, one has to bring the possibility of Gaucher Disease. Early diagnosis, timely ERT can lead to eventless outcome.

 

BIBLIOGRAPHY

  1. Kliegman R, Blum NJ, Tasker RC, Wilson KM, St. Geme JW III, Schuh AM, Mack CL, editors. Nelson textbook of pediatrics. 22nd ed. Vol 1. Philadelphia, PA: Elsevier; 2025; p890-891.
  2. Nyhan WL, Hoffmann GF, editors. Atlas of Inherited Metabolic Diseases. 4th ed. CRC Press; 2020; p678-687.
  3. Zhu J, Sun Y, Zheng Wand WangC(2023) Case report: Multidisciplinary collaboration in diagnosis and treatment of child gaucher Front. Pediatr. 11:1057574. doi: 10.3389/fped.2023.1057574/
  4. Das Approach to a child with pallor and hepatosplenomegaly. In: Practical Pediatric Hematology, 3rd ed. 2018;119–126.
  5. Patel K, Shah P, Shah R, Mishra S. Gaucher disease: a case Indian J Pathol Oncol. 2024;11(2):213–215.
Recommended Articles
Original Article Open Access
Evaluating the Duration of Postop Analgesia Following Ultrasound Guided Transversalis Fascia Plane Block In Patients Undergoing Open Inguinal Hernia Surgery
2026, Volume-7, Issue 1 : 383-393
DOI: 10.5281/zenodo.18248560
Original Article Open Access
Analgesic Efficacy of Combined Intrarectal Lidocaine Gel with Periprostatic Nerve Block Versus Caudal Block: A Single-Center Experience from A Tertiary Care Hospital
2026, Volume-7, Issue 1 : 372-376
DOI: 10.5281/zenodo.18248227
Original Article Open Access
Study comparing platelet indices between stable angina, acute coronary syndrome with age sex matched normal controls
2025, Volume-6, Issue 6 : 2156-2160
Original Article Open Access
Outcomes in Retrograde Intrarenal Surgery: A Three Year Retrospective Study
2026, Volume-7, Issue 1 : 322-327
International Journal of Medical and Pharmaceutical Research journal thumbnail
Volume-7, Issue 1
Citations
49 Views
304 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
facebook twitter linkedin mendeley research-gate
© Copyright | International Journal of Medical and Pharmaceutical Research | All Rights Reserved